RxDoctor Payments DataLook up a doctor →

Robert Bruno, DO

Nephrology · Brick, NJNPI 1740220730

Payments from drug & device makers

$9,205in general payments, 2019–2025

Across 407 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$628
  • Otsuka America Pharmaceutical, Inc.$602
  • Novo Nordisk$570
  • GSK$567
  • AbbVie$495
  • plus $4K from 31 others

What the payments were for

  • Food & beverage$8,90997%
  • Education$2953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,205 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$407,635
Medicare patients
1,159
Services billed
2,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$249,408
FarxigaDapagliflozin Propanediol130$165,838
JardianceEmpagliflozin43$66,092
OzempicSemaglutide19$29,063
JanuviaSitagliptin Phosphate11$17,635
LokelmaSodium Zirconium Cyclosilicate16$16,224
Potassium Citrate ErPotassium Citrate83$9,184
Calcitriol204$4,624
Irbesartan128$2,496
Sodium Polystyrene Sulfonate23$2,401
Potassium Chloride83$2,190
Sevelamer Carbonate11$2,129
Nifedipine ErNifedipine59$2,033
Febuxostat20$1,988
Amlodipine Besylate224$1,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$602$249,40813 claims
AstraZenecaFarxiga, Lokelma$1,998$182,062146 claims
Boehringer IngelheimJardiance$420$66,09243 claims
Novo NordiskOzempic$570$29,06319 claims
ANI Pharmaceuticals, Inc.Valsartan$59$1,92151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →